Oncology Institute (TOI) EBIAT (2020 - 2026)

Oncology Institute (TOI) has 7 years of EBIAT data on file, last reported at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT rose 87.28% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$43.5 million (up 32.39% YoY), and the FY2025 full-year result was -$60.6 million, up 6.27% from the prior year.
• EBIAT for Q1 2026 stood at -$2.5 million, up from -$7.5 million in the prior quarter.
• Across five years, EBIAT topped out at $19.3 million in Q1 2022 and bottomed at -$30.0 million in Q1 2023.
• The 5-year median for EBIAT is -$16.1 million (2024), against an average of -$12.4 million.
• The widest annual swing landed in 2022, when EBIAT soared 2036.35%; it then plunged 551.42% in 2023.
• A 5-year view of EBIAT shows it stood at -$11.0 million in 2022, then tumbled by 70.38% to -$18.8 million in 2023, then rose by 29.71% to -$13.2 million in 2024, then surged by 43.04% to -$7.5 million in 2025, then jumped by 66.81% to -$2.5 million in 2026.
• The last three EBIAT figures came in at -$2.5 million (Q1 2026), -$7.5 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.

Peer Comparison